Boston Scientific to acquire Penumbra in $14.5B deal

Boston Scientific agreed to acquire Penumbra for $374 per share in a deal that values the target at roughly $14.5 billion enterprise value, with shareholders able to elect $374 cash or 3.8721 Boston Scientific shares (approximately 73% cash / 27% stock). Boston Scientific will fund about $11 billion of the cash portion with cash on hand and new debt; Penumbra projects ~ $1.4 billion revenue for 2025 (~17% YoY growth). The deal is expected to close in 2026 pending approvals, and Boston Scientific forecasts adjusted EPS dilution of $0.06–$0.08 in the first full year, turning neutral to slightly accretive in year two and more accretive thereafter; market reaction showed PEN up ~12% and BSX down ~4.5% on the announcement.

Analysis

Market structure: Penumbra shareholders and short-term arburs are the clear winners (offer $374/share, ~+6.9% from $350); Boston Scientific (BSX) faces immediate equity dilution (guidance -$0.06 to -$0.08 EPS in year 1) and ~ $11bn incremental debt, shifting pricing power modestly toward consolidated neurovascular device suppliers (MDT, SYK to feel competitive pressure). The deal tightens supply-side concentration in mechanical thrombectomy/embolization where PEN reported ~$1.4bn revenue (2025 est., +17% YoY), implying higher combined share in a fast-growing end-market driven by aging demographics.

Risk assessment: Tail risks include deal failure (shareholder/regulatory) that could drop PEN toward pre-announcement levels (~-10–20%), financing stress if BSX leverage pushes rating agencies to widen credit spreads, and integration/recall risk for device lines; expect immediate volatility (days), diligence and financing updates over weeks–months, and accretion materializing in 2+ years per BSX guidance. Hidden dependencies: hospital reimbursement trends and catheter supply chains; catalysts are shareholder vote, announced financing details, FDA/regulatory signals and rating agency actions.

Trade implications: Direct arb: buy PEN up to $370 (scale 2–4% portfolio) aiming for $374 exit at close; hedge with short BSX via the exchange ratio (3.8721 BSX per PEN) to neutralize market risk. Options: buy 12-month BSX puts (strike ~80) sized to cover 1–2% equity exposure if downside >10%; sell short-dated PEN covered calls only if premium >2% monthly. Sector: underweight unhedged BSX exposure for 3–12 months; overweight standalone neurovascular pure-plays that are not being leveraged by M&A.

Contrarian angles: The market may underprice long-run accretion — if BSX falls >10% from ~$90 to <$81, establish a 1–2% opportunistic long because guidance shows neutral/slightly accretive by year two. Arbitrage spread may compress quickly; if PEN approaches $372 (spread <$2), abandon buy-and-hold arb. Watch for >50bp widening in BSX 5y CDS or a rating watch — that’s the trigger where bond yields present a buying opportunity vs equity.

Key Decisions for Investors

• Establish a 2–4% portfolio long position in PEN (buy up to $370) as an event-arb with target exit at $374 on close; trim if spread compresses to <$2 or if regulatory concerns are publicly flagged (vote/filing delays beyond 90 days).
• Implement a hedged pair: for each PEN share bought, short 3.8721 BSX shares to neutralize market beta; size trades to keep net delta ~0. Rebalance if BSX moves >5% intraday or if Boston Scientific issues definitive financing terms.
• Purchase protective BSX puts: buy 12-month BSX 80 strikes (or nearest OTM) sized to cover 1–2% portfolio exposure to hedge potential deleveraging/rating actions; consider rolling if put implied vol >30% to preserve cost basis.
• Do not add new BSX corporate bond exposure until BSX 5y CDS widens by >50bps or investment-grade spread exceeds +150bps over Treasuries; if that threshold is met, consider buying bonds at the wider spread as a higher-probability contrarian play (target yield pickup >150bps).